Actively Recruiting
Study Evaluating the Safety and Effects of Tilrekimig Compared to Placebo in Adolescents and Adults with Severe Asthma
Led by Pfizer · Updated on 2026-10-30
1100
Participants Needed
16
Research Sites
12 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effects of tilrekimig, a study medicine being tested for severe asthma. The trial focuses on people who have had severe asthma for at least 12 months and experienced two or more asthma attacks in the past year. This phase 3 study aims to understand how tilrekimig compares to placebo shots in improving asthma symptoms and reducing attack rates. Participants will receive either tilrekimig or a placebo through subcutaneous injections administered at the study clinic. The study uses a randomized, double-blind design with parallel groups to compare outcomes. Treatment and observation take place over a 52-week period, with additional monitoring of safety up to 64 weeks. During the study, participants will have regular assessments including lung function tests, symptom questionnaires, and monitoring for asthma exacerbations and safety events. Researchers will measure the annual rate of asthma attacks, lung function changes, quality of life, and other asthma control indicators. The total duration for participant involvement is up to 64 weeks, including follow-up for adverse events.
CONDITIONS
Brief Title
A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here